Additionally, in patients with RA and no evidence of clinical HF, tocilizumab treatment has been associated with reductions in NT-proBNP levels (median 42.5 pg/mL vs. 109.0 pg/mL, p < 0.001), suggesting a potential early benefit in alleviating inflammation-related cardiac stress prior clinical manifestation of HF [129]. This evidence concerns the gene NPPB and hydrops fetalis.